Plate Nº 26 · recorded September 30, 2026
Health & Medicine ResearchReported finding
Japanese Hospital Performs World-First Surgery With iPS Heart Cells
Surgeons in Japan have transplanted sheets of lab-grown heart muscle into a woman in her 50s — the first clinical use of an iPS cell therapy approved in March.
By Nathan Brooks3 min read552 words
In brief
- A Japanese hospital performed the world's first surgery using sheets of heart muscle cells grown from iPS cells on a woman in her 50s.
- The therapy received conditional government approval in March; trials on eight ischemic heart disease patients eased symptoms in all eight, with improved heart function in four.
- Yoshiki Sawa's team plans to treat 75 patients by 2033, with full authorization expected only after seven years of safety and efficacy evaluation.
Surgeons in Japan have performed the world's first operation using sheets of commercially available heart muscle cells grown from stem cells, one of the surgeons said. The procedure took place on Tuesday at a Japanese hospital and lasted about an hour.
The patient, a woman in her 50s, received transplants of thin sheets made of muscle cells derived from induced pluripotent stem cells, or iPS cells. These are mature cells that scientists have reprogrammed back into an immature, flexible state — in effect, giving them a second chance to become almost any cell type in the body without requiring an embryo.
The surgery marks the first clinical use of the therapy since it received conditional government approval in March.
"Our hope is that this will improve the patient's quality of life," Yoshiki Sawa, the surgeon who led the operation and heads Osaka Keisatsu Hospital, told reporters afterwards.
What the trials showed
Before approval, researchers tested the therapy on eight patients with ischemic heart disease — a condition in which narrowed heart arteries damage the heart muscle by restricting its blood supply. According to Japanese media reports, all eight patients experienced relief from their symptoms, and four of them showed measurable improvement in heart function.
Those results are promising, but they come from a small group. The earlier trials were not designed to prove the therapy works at scale, and the full picture of its benefits and risks will only emerge over the coming years.
How the treatment is meant to work
Sawa developed the technology together with Shinya Yamanaka, the Japanese scientist who won the 2012 Nobel Prize for his research on iPS cells. Because iPS cells can develop into any cell in the body, researchers can grow them into heart muscle in the laboratory and assemble the cells into sheets.
Surgeons then attach these sheets to a failing heart. The goal is to strengthen the heart muscle, which should ease heart failure symptoms, improve cardiac performance, and increase how much exercise patients can tolerate.
The therapy is aimed primarily at heart patients who have run out of other treatment options — a group that currently has few alternatives.
What happens next
Sawa's team plans to operate on 75 patients by 2033 and report on how well the treatment works, according to media reports. The Asahi Shimbun daily reported that Japan will grant full authorization only after the therapy's benefits and safety are proven over the next seven years.
In other words, Tuesday's surgery is the beginning of a long evaluation process, not the final word on the treatment.
A broader shift in regenerative medicine
The heart therapy is part of a wider push in Japan to turn iPS cells into treatments. In March, the country also granted conditional approval to a Parkinson's disease therapy that transplants iPS cells into a patient's brain, following a successful clinical trial.
If the current seven-year evaluation confirms the heart therapy's safety and effectiveness, it could become a standard option for patients with severe heart failure — a condition that affects millions worldwide and often leads to transplant lists or limited survival.
For now, though, the milestone belongs to one woman in her 50s and the surgical team that placed lab-grown heart muscle inside her chest for the first time.
via Medical Xpress (Source)
More from Nathan Brooks
Nearby plates
- Scientists Find the Stem Cell That Builds Tendons and Ligaments
- FDA Approves First Heart Valve That Grows With a Child
- Gene Transcription Speed Emerges as New Target for Vascular Disease
- Nearly 1 in 3 Diabetes Patients Face Kidney, Heart Disease or Death
- Short Steroid Courses Raise Pneumonia and Heart Failure Risk in Diabetes